Kronos Bio, Inc. (KRON)
NASDAQ: KRON · Real-Time Price · USD
0.8250
0.00 (0.00%)
At close: Mar 28, 2025, 4:00 PM
0.8356
+0.0106 (1.28%)
After-hours: Mar 28, 2025, 7:46 PM EDT

Company Description

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States.

Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.

The company was incorporated in 2017 and is headquartered in San Mateo, California.

Kronos Bio, Inc.
Kronos Bio logo
Country United States
Founded 2017
IPO Date Oct 9, 2020
Industry Biotechnology
Sector Healthcare
Employees 10
CEO Deborah Knobelman

Contact Details

Address:
1300 South El Camino Real, Suite 400
San Mateo, California 94402
United States
Phone 650 781 5200
Website kronosbio.com

Stock Details

Ticker Symbol KRON
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001741830
CUSIP Number 50107A104
ISIN Number US50107A1043
SIC Code 2834

Key Executives

Name Position
Dr. Deborah A. Knobelman Ph.D. Interim Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and President
Joshua A. Kazam Co-Founder and Director
David M. Tanen J.D. Secretary and Director

Latest SEC Filings

Date Type Title
Mar 18, 2025 10-K Annual Report
Mar 18, 2025 8-K Current Report
Dec 27, 2024 8-K Current Report
Nov 27, 2024 8-K Current Report
Nov 14, 2024 EFFECT Notice of Effectiveness
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Nov 12, 2024 UPLOAD Filing
Nov 7, 2024 8-K Current Report